RE
FATE icon

RBC Europe’s Fate Therapeutics FATE Stock Holding History

RBC Europe’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1K Hold
60
– – ﹤0.01% 597
2022
Q1 		$2K Buy
+60
New +$2.32K ﹤0.01% 595

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

RBC Europe's FATE Position: Q2 2022 in Review

RBC Europe held its Fate Therapeutics (FATE) position steady in Q2 2022 at 60 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #597.

RBC Europe first reported a position in FATE in Q1 2022 and has held it in 2 quarters since. The position peaked at $2K in Q1 2022. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • RBC Europe held 60 shares of Fate Therapeutics worth $1K as of Q2 2022.
  • RBC Europe left its Fate Therapeutics share count unchanged in Q2 2022.
  • Fate Therapeutics made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #597 holding.
  • RBC Europe first reported a position in Fate Therapeutics in Q1 2022 and has held it in 2 quarters since.
  • RBC Europe's Fate Therapeutics position peaked at $2K in Q1 2022.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.